Albert Matalon, MD
Nephrology · New York, NYNPI 1033174834
Payments from drug & device makers
What this record shows
This record is dominated by education: $125 of the $125 with a category attached, or 100.0%. 3 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 49.0% of the total. Reporting peaked in 2019 at $61 and has fallen 59.8% since, to $25 in 2024. That places this record below the midpoint for nephrology clinicians in NY, where the typical reported total is $564.
Across 3 payments — averaging $41.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$61
- GSK$39
- Akebia Therapeutics Inc$25
Across 404 payments — averaging $967.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$390K
- Ardelyx, Inc.$1K
What the payments were for
- Education$125100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| GSK | 1 | $39 |
| Akebia Therapeutics Inc | 1 | $25 |
How this compares
$125 in reported general payments places this provider in the 20th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 71 | $45,205 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 33 | $13,890 |
| JardianceEmpagliflozin | 23 | $13,169 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $8,468 |
| Sevelamer Carbonate | 33 | $7,469 |
| Paricalcitol | 13 | $3,700 |
| ProsolParenteral Amino Acid 20% No.1 | 20 | $3,457 |
| Calcium Acetate | 21 | $2,881 |
| Calcitriol | 185 | $2,782 |
| Esomeprazole Magnesium | 11 | $2,720 |
| Potassium Citrate ErPotassium Citrate | 20 | $1,359 |
| Atorvastatin Calcium | 137 | $950 |
| Allopurinol | 144 | $907 |
| Bumetanide | 20 | $574 |
| Amlodipine Besylate | 90 | $557 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New York
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
- Jai RadhakrishnanNew York$369K
- Girish NadkarniNew York$281K
- James ChevalierNew York$202K
- David CharytanNew York$164K
- Kirk CampbellNew York$152K
- Andrew BombackNew York$106K
- Alan PerlmanNew York$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.